Clinical Trial NameClinical Trial Full TitlePrincipal InvestigatorProject site statusClinical trials gov number
(CCTG) OVC.2 / NRG-GY005A Randomized Phase II/III Study of the Combination of Cediranib and Olaparib Compared to Cediranib or Olaparib Alone, or Standard of Care Chemotherapy in Women With Recurrent Platinum-Resistant or -Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (COCOS)Hirte, Dr HalOpen to recruitmentNCT02502266
(Merck) MK-7902-001 / E7080-G000-313 / LEAP-001A Phase 3 Randomized, Open-Label, Study of Pembrolizumab (MK-3475) Plus Lenvatinib Versus Chemotherapy for First-line Treatment of Advanced or Recurrent Endometrial CarcinomaHirte, Dr HalOpen to recruitmentNCT03884101
(Tesaro) 3000-03-005 / ENGOT-OV44 / FIRSTA Patient Centric Randomized Phase 3 Comparison of Standard of Care Platinum Based Therapy to the Same Plus TSR-042 As First Line Treatment of Patients with Stage III or IV Non-Mucinous Ovarian Cancer.Hirte, Dr HalOpen to recruitmentNCT03602859
(UHN) BioDIVABiomarker Discovery Project in High Grade Serous Ovarian CancerElit, Dr LaurieRecruitment on hold - COVID-19NCT03419689
Download PDF